Title:
PROTEINS BINDING NKG2D, CD16 AND FLT3
Document Type and Number:
Japanese Patent JP2023106433
Kind Code:
A
Abstract:
To provide proteins that bind NKG2D, CD16, and tumor-associated antigen FLT3.SOLUTION: A protein comprises: (a) a first antigen-binding site that binds NKG2D; (b) a second antigen-binding site that binds FLT3; and (c) an antibody Fc domain or a portion thereof sufficient to bind CD16, or a third antigen-binding site that binds CD16. In one embodiment, the first antigen-binding site comprises a heavy chain variable domain and a light chain variable domain to bind the human NKG2D.SELECTED DRAWING: Figure 1
Inventors:
GREGORY P CHANG
ANN F CHEUNG
WILLIAM HANEY
BRADLEY M LUNDE
BIANKA PRINZ
ANN F CHEUNG
WILLIAM HANEY
BRADLEY M LUNDE
BIANKA PRINZ
Application Number:
JP2023075458A
Publication Date:
August 01, 2023
Filing Date:
May 01, 2023
Export Citation:
Assignee:
DRAGONFLY THERAPEUTICS INC
International Classes:
C07K16/46; A61K39/395; A61P35/00; A61P35/02; A61P43/00; C07K16/28
Attorney, Agent or Firm:
Toru Ishikawa
Previous Patent: Mechanism-based quality control for herbal medicines
Next Patent: regulatory T cell epitopes
Next Patent: regulatory T cell epitopes